Alberto Costa MD is Scientific Director and CEO of the European School of Oncology (ESO), established in Milan in 1982 as a private non profit educational organisation in cancer medicine (www.eso.net). He is also Editor of the School’s magazine, CancerWorld, available online at www.cancerworld.org
Costa was trained in Milan in cancer surgery and particularly in breast cancer management. He is Breast Unit Clinical Director at Multimedica, Milan, Italy, and Chair of the Advisory Board of the Canton Ticino Breast Unit, Lugano, Switzerland. Both of these units are certified by EUSOMA (European Society of Mastology). He is one of the editors of the journal The Breast and a member of the editorial boards of some leading cancer publications including the European Journal of Cancer and Nature Reviews Clinical Oncology. He has authored over 200 scientific publications.
Previously he has served as Secretary General of the European Organisation for the Research and Treatment of Cancer (EORTC) and Federation of European Cancer Societies (FECS). He was a member of the European Commission's Europe Against Cancer programme and currently seats in the Commission’s Committee of Cancer Experts representing ECCO (the European CanCer Organization, Brussels) of which he is a Board member.
At national level he has played a key role in the creation of the Italian School of Senology and of the European Institute of Oncology in Milan.Internationally recognized for his work for the advancement of breast cancer management and the recipient of several awards, Dr Costa is also renowned for his innovative ideas in scientific communication and educational development, specifically the training of doctors. As Director of the European School of Oncology, his work has helped elevate the standards of training and medical care in the field of cancer globally. He has actively encouraged the establishment of collaborative relationships with international organizations and institutes thus promoting the essential sharing of knowledge and experience everywhere for the widest benefit of cancer patients.